X4 Pharmaceuticals

XFORNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$340.073 M

$3.43 -1.86%

Close of 22 Sept 2026

Revenue

$6.50M

#3239 by revenue

Earnings

-$79.2M

Loss-making

Shares outstanding

99,146,743

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#79OcugenOCGN$352.7M
#80Century TherapeuticsIPSC$342.2M
#81X4 PharmaceuticalsXFOR$340.1M
#82Lexeo TherapeuticsLXEO$333.9M
#83Inhibikase TherapeuticsIKT$322.3M

What if X4 Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.2T

$304,941.63

Per share 88,904× higher

Bitcoin $1.74T

$17,566.44

Per share 5,121× higher

Nvidia $5.52T

$55,632.36

Per share 16,219× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for X4 Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.